Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
BJD, 2023.
Alabas OA, Mason KJ, Yiu ZZN, Warren RB, Lunt M, Smith CH, Griffiths, CEM; BADBIR Study Group
Read publication: BJD
Related
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study...
Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoria...
Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic ...
0 Comments